All In Biotech

Drug Trial Radar · NCT03845387

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Feb 26, 2019

Primary completion

Feb 21, 2020

Study completion Feb 21, 2020

Sponsor

Sponsor type
Industry
First posted
Feb 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

Conditions

  • Parkinson Disease

Interventions

  • KDT-3594Drug

    oral administration, dose titration

  • PramipexoleDrug

    ER formulation, oral administration, dose titration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scoreTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.